Top

Current Treatment Options in Oncology

Published in:

01-06-2008 | Malignant Mesothelioma

Peritoneal Mesothelioma

Authors: Mary E. Hesdorffer, MS, APRN-BC, John Chabot, MD, Carolyn DeRosa, BA, Robert Taub, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 2-3/2008

Title: Peritoneal Mesothelioma
Authors: Mary E. Hesdorffer, MS, APRN-BC
John Chabot, MD
Carolyn DeRosa, BA
Robert Taub, MD, PhD
Publication date: 01-06-2008
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 2-3/2008
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-008-0072-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 2-3/2008

Mind–Body Interventions in Oncology

Treatment of Malignant Ascites

Herbs and Other Botanicals in Cancer Patient Care

Exercise in Prevention and Management of Cancer

Systemic Treatments for Mesothelioma: Standard and Novel

Introduction to Section on Integrative Oncology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer